Advanced Prostate Cancer VL

18F Fluorocholine PET-Whole Body MR in the Staging of High Risk Prostate Cancer - Ur Metser

Details
Ur Metser a study that was conducted to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging. Biography: Ur Metser, MD, FRCPC, Joint Department of Medical Imaging, the University of Toronto Related Content: 18F-Fluorocholine PET Whole-Bo...

68Ga PSMA 11 PET MRI in Intermediate and High Risk Prostate Cancer - Claudia Zacharias

Details
Claudia Zacharias presents Gallium 6 PSMA-11 PET/MR Imaging in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer, a pilot study evaluating the detection rate for the initial diagnosis of prostate cancer and the metastatic spread for patients in the intermediate and high-risk prostate cancer risk category using 68 Ga-PSMA-11 PET/MR. She reviews the potential role of 68 Ga-PSM...

A Review of Imaging Modalities in Prostate Cancer - Peter Pinto

Details
(Length of Interview: 17 min) Peter Pinto highlights the paradigm shift to the use of new imaging technology for a more accurate diagnosis of prostate cancer. Targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18) as a staging tool, with mention of metabolic and focal imaging are part of this comprehensive interview. As...

Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus ADT for Men with Advanced Prostate Cancer - Tom Keane

Details
(Length of video: 9 min) Tom Keane reviews an article entitled, “Comparative Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus Androgen Deprivation Therapy for Men with Advanced Prostate Cancer”. Men with locally advanced prostate cancer or regionally advanced prostate cancer treated initially with radical prostatectomy plus radiation had a lower risk of pr...

A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney

Details
(Length of Conversation: 18 min) Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute Alicia Morgans, MD, MPH Related Content: 12-Year Follow-Up of GETUG-12, A Pha...

Targeting Treatment to Subtypes in Prostate Cancer - Misha Beltran

Details
Misha Beltran and Alicia Morgans discuss treatment selection for patients with unique molecular subtypes. They discuss the use of ADT in this patient population as well as chemotherapy. Interestingly, they highlight the shared alteration and learnings from the study of small cell lung cancer. Biographies: Himisha Beltran, MD, Medical Oncologist, Dana Farber Cancer Institute, Harvard Medical School...

Quality of Life and Health Economics Data: STAMPEDE Trial - Nick James

Details
Nick James and Alicia Morgans discuss the quality of life and health economics data from the docetaxel part of the STAMPEDE trial. They also review data presented by Chris Parker on the use of radiotherapy to the primary tumor for men with newly-diagnosed metastatic prostate cancer. Biographies: Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR...

ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle Burgess

Details
(Length of Discussion: 12 min) Alicia Morgans and Earle Burgess discuss the details of the investigator-initiated trial called ENZADA. They discuss the “why” behind the design of this Phase II trial. Their desire is to understand whether or not triplicate therapy with ADT, plus docetaxel, plus a next gen endocrine agent will further improve outcome over either agent alone in this patient populatio...

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial - Fred Saad

Details
Alicia Morgans and Fred Saad dialogue about the details of this phase 3 trial by the Quebec Cooperative Group of Radiation Oncologists in patients with high-risk localized prostate cancer. The aim of this superiority randomized trial was to compare outcomes of RT combined with either 36 or 18 months of ADT. Biographies: Fred Saad, MD FRCS Professor and Chief of Urologic Oncology, University of Mon...

Genetic Screening for Patients with Prostate Cancer - Todd Morgan

Details
Todd Morgan shares the unique program that he and his GU team at the University of Michigan have implemented in an effort to gain a better understanding of the genetics and genomics involved with progression in prostate cancer. Biographies: Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies and an Associate Professor of Urology and has been at...
email news signup